pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 22·1 min read
save

Survey Finds 24% of U.S. Workers Stay in Unwanted Jobs to Keep Health Insurance

Jul 22, 2026·read at STAT ↗Negative

A Gallup and West Health survey of more than 2,000 employed adults found that 24% would stay in a job they dislike simply to retain health insurance coverage.

The phenomenon, known as job lock, has long limited workers’ ability to change jobs or start businesses, especially for those with chronic health conditions who fear losing benefits.

The share of workers reporting job lock rose from 16% in 2021 to the current 24%, reflecting growing anxiety about health‑care costs and economic uncertainty.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: More workers hate their jobs, but keep them for the health insurance”

read at STAT ↗
541 words · retrieved Jul 22
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.3
drugs
Rare Disease3
topics
Rare Disease3

related stories

  • May 12STAT+: Hims’ sales miss as telehealth competition growsSTAT
  • May 12STAT+: Capsida says it still doesn’t know what caused gene therapy deathSTAT
  • May 12A year after Vertex’s big launch, pain drug research faces a pivotal momentBioPharma Dive
  • May 11No FDA permission, no problem: New flavored vape policy worries expertsSTAT
  • May 11STAT+: Astellas treatment offers new hope to a devastated rare disease communitySTAT